Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus rhamnosus extract refers to a preparation derived from the L. rhamnosus species, a Gram-positive, non-pathogenic, probiotic bacterium commonly found in the gastrointestinal tract and widely used in dietary supplements, functional foods, and research. The species, formerly classified as Lactobacillus rhamnosus, is known for its beneficial effects on intestinal health, modulation of the immune system, and inhibition of pathogenic bacteria. Extracts typically contain either live, heat-killed, or lysed bacterial cells and/or their metabolic byproducts, and are marketed for digestive support, mitigation of antibiotic-associated or infection-related diarrhea, reduction of eczema in children, and enhancement of overall gut barrier integrity. The mechanism of action is primarily microbiome modulation, competitive inhibition of pathogens, immune support, and promotion of epithelial barrier function, including upregulation of tight junction proteins and metabolic modulation of host signaling pathways[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lacticaseibacillus rhamnosus extract.